33% is significant in the scheme of where they should be now. The others may not be at the same timeline, and unfortunately, even IF they have continued to deteriorate it has been at a much slower timeframe.
Which also concludes, this is the best drug soon to be on the market to date.
Remember its a orphan drug.
Ann: OLE Study update reveals impressive Survival Data, page-212
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.3¢ |
Change
-0.008(4.17%) |
Mkt cap ! $83.90M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 17.3¢ | $59.77K | 338.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 376984 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 25091 | 2 |
View Market Depth
| Last trade - 15.42pm 13/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |